PET quantification of 5-HT(2A) receptors in the human brain: A constant infusion paradigm with [18F]altanserin

Journal of Nuclear Medicine

Volumn 41, Issue 2, 2000, Pages 234-241

  Van Dyck, Christopher H ^a   Tan, Ping Zhong ^b   Baldwin, Ronald M ^b   Amici, Louis A ^b   Garg, Pradeep K ^b   Ng, Chin K ^b   Soufer, Robert ^b   Charney, Dennis S ^b   Innis, Robert B ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

5 HT(2A) receptor; 18F altanserin; PET; Serotonin

Indexed keywords

ALTANSERIN; FLUORINE 18; SEROTONIN 2A RECEPTOR;

ADULT; ARTICLE; DEPRESSION; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; ISOTOPE LABELING; MALE; MATHEMATICAL ANALYSIS; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RECEPTOR BINDING; RECEPTOR DENSITY; SCHIZOPHRENIA;

ADULT; BRAIN; FEASIBILITY STUDIES; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INFUSIONS, INTRAVENOUS; KETANSERIN; LINEAR MODELS; MALE; RECEPTORS, SEROTONIN; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033962092     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Arango V, Ernsberg P, Mazuk PM, et al. Autoradiographic demonstration of increased 5-HT2 and ß-adrenergic receptors in the brains of suicide victims. Arch Gen Psychiatry. 1990;47:1038-1047.
2. Stanley M, Mann JJ. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet. 1983;2:214-216.
3. Mita T, Hanada S, Nishino N, et al. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry. 1986;21:1407-1414.
4. Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia: a postmortem study. Arch Gen Psychiatry. 1993;50:810-818.
5. Marcusson JO, Morgan DG, Winblad B, Finch CE. Serotonin-2 binding sites in human frontal cortex and hippocampus: selective loss of S-2A sites with age. Brain Res. 1984;311:51-56.
6. 2 receptors in senile dementia of the Alzheimer type. Neurosci Lett. 1984;44:47-51.
7. Cross AJ, Crow TJ, Ferrier IN, Johnson JA. The selectivity of the reduction of serotonin S2 receptors changes in Alzheimer-type dementia. Neurobiol Aging. 1986;7:3-7.
8. Pike VP. Radioligands for PET studies of central 5-HT receptors and re-uptake sites - current status. Nucl Med Biol. 1995;22:1011-1018.
9. Wong DF, Wagner HN, Jr, Dannals RE, et al. Effects of age on dopamine and serotonin receptors measured by positron emission tomography in the living human brain. Science. 1984;226:1393-1396.
10. 18F-labeled setoperone. J Neurochem. 1990;54:1744-1754.
11. Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christians L. Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J Nucl Med. 1991;32:2266-2272.
12. 2A receptors with positron emission tomography. Life Sci. 1996;58:187-192.
13. Leysen JE. Use of 5-HT receptor agonists and antagonists for the characterization of their respective receptor sites. In: Boulton AB, Baker GB, Jurio AV, eds. Drugs as Tools in Neurotransmitter Research. Neuromethods. Vol 12. Clifton, NJ: The Humana Press; 1989:299-349.
14. Mathis C, Choi Y, Simpson N, Mintun M. In vivo studies of 5-HT2 receptors in monkeys using F-18 altanserin [abstract]. Soc Neurosci Abst. 1994;20:1546.
15. Tan P-Z, Baldwin RM, van Dyck CH, et al. Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [F-18]altanserin in human and rodent. Nucl Med Biol. 1999;26:601-608.
16. 2 receptors in humans using positron emission tomography. Eur J Nucl Med. 1994;21:937-946.
17. 18F]altanserin: results in young normal controls. J Cereb Blood Flow Metab. 1995;15:787-797.
18. Mintun M, Price J, Smith G, et al. Quantitative 5-HT2A receptor imaging in man using F-18 altanserin: a new model accounting for labeled metabolites [abstract]. J Nucl Med. 1996;37:109P.
19. 18F]altanserin in the human brain. Synapse. 1998;30:380-392.
20. Mason NS, Huang Y, Holt DP, Perevuznik JJ, Lopresti BJ, Mathis CA. Synthesis and characterization of [F-18]4-(4-fluorobenzoyl)piperidine, an [F-18]altanserin metabolite [abstract]. J Nucl Med. 1997;38:56P.
21. 18F]4-(4-fluorobenzoyl)piperidine. J Labelled Compds Radiopharm. 1997;40:SI 161-162.
22. Frey KA, Ehrenkauter LE, Beaucage S, Agranoff BW. Quantitative in vivo receptor binding I. Theory and application of the muscarinic cholinergic receptor. J Neurosci. 1985;5:421-428.
23. 18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab. 1993;13:24-42.
24. 18F]altanserin, radioligand for imaging of 5-HT2A receptor in brain with positron emission tomography. Appl Radiat Isot. 1999;50:923-927.
25. Monclus M, Luxen A. A convenient synthesis of 4-nitrophenyl 4-piperidinyl ketone. Organ Prep Pro Int. 1992;24:692-694.
26. USP XXIII. Sterility tests 〈71〉. In: The United Stales Pharmacopeia. 23rd rev ed. Rockville, MD: United States Pharmacopeial Convention; 1995:1686-1690.
27. Mullani NA, Gould KL, Hartz RK, et al. Design and performance of Posicam 6.5 BGO positron camera. J Nucl Med. 1990;31:610-616.
28. Matsui T, Hirano A. An Atlas of the Human Brain for Computerized Tomography. Tokyo, Japan: Igaku-Shoin, Ltd; 1978.
29. Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB. Evaluation of ultrafiltration for the free fraction determination of single photon emission computed tomography (SPECT) tracers: ß-CIT, IBF, and iomazenil. J Pharm Sci. 1994;83:1014-1019.
30. Mintun MA, Raichle ME, Kilboum MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol. 1984;15:217-227.
31. 2-receptors in human brain. Brain Res. 1983;276:231-235.
32. Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain. IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience. 1987;21:123-139.
33. De Keyser J, Clayes A, De Backer JP, Ebinger G, Roels F, Vauquelin G. Autoradiographic localization of D1 and D2 receptors in the human brain. Neurosci Lett. 1988;91:142-147.
34. 123I]iomazenil binding to benzodiazepine receptors in nonhuman primates. I. Kinetic modeling of single bolus experiments. J Cereb Blood Flow Metab. 1994;14:439-452.
35. 11C]-methyl)-2-Br-LSD. Synapse. 1987;1:393-398.
36. 18F]altanserin and positron emission tomographic imaging. Psychiatry Res Neuroimaging. 1996;68:11-22.
37. 18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. Brain Res. 1998;813:167-171.
38. Tan P-Z, Baldwin RM, Fu T, Charney DS, Innis RB. Rapid synthesis of F-18 and H-2 dual-labeled altanserin, a metabolically resistant PET ligand for 5-HT2A receptors. J Labelled Compds Radiopharm. 1999;42:457-467.
39. 2 receptor study with PET. Clin Neuropharmacol. 1992;15(suppl 1):202.
40. Blin J, Baron J, Dubois B, et al. Loss of brain 5-HT2 receptors in Alzheimer's disease. Brain. 1993;116:497-510.